Diabetic Neuropathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Diabetic Neuropathy – Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics, Inc.

Araim Pharmaceuticals, Inc.

Celgene Corporation

Commence Bio, Inc.

Glucox Biotech AB

KPI Therapeutics, Inc.

Lpath, Inc.

Medifron DBT Co., Ltd.

Neuralstem, Inc.

NovaLead Pharma Pvt. Ltd.

Novartis AG

Omeros Corporation

PhiloGene, Inc.

Reata Pharmaceuticals, Inc.

Relief Therapeutics S.A.

Sucampo Pharmaceuticals, Inc.

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathy Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Neuropathy - Overview 10

Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11

Diabetic Neuropathy - Therapeutics under Development by Companies 12

Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14

Diabetic Neuropathy - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Diabetic Neuropathy - Products under Development by Companies 18

Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20

Diabetic Neuropathy - Companies Involved in Therapeutics Development 21

Achelios Therapeutics, Inc. 21

Araim Pharmaceuticals, Inc. 22

Celgene Corporation 23

Commence Bio, Inc. 24

Glucox Biotech AB 25

KPI Therapeutics, Inc. 26

Lpath, Inc. 27

Medifron DBT Co., Ltd. 28

Neuralstem, Inc. 29

NovaLead Pharma Pvt. Ltd. 30

Novartis AG 31

Omeros Corporation 32

PhiloGene, Inc. 33

Reata Pharmaceuticals, Inc. 34

Relief Therapeutics S.A. 35

Sucampo Pharmaceuticals, Inc. 36

ViroMed Co Ltd 37

Diabetic Neuropathy - Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 42

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

atexakin alfa - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

benfotiamine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

BNV-222 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

cibinetide - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CMB-200 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Cyndacel-M - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

EMA-401 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ketoprofen - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Lpathomab - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

MDR-652 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ND-07 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

NLP-198 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

NSI-189 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

NSI-566 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

OMS-721 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

PDA-002 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

pirenzepine hydrochloride - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

RTA-901 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

RTU-1096 - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Small Molecule for Pain - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Small Molecules for Diabetic Neuropathy - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

U-2902 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

VM-202 - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

XK-568b - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Diabetic Neuropathy - Dormant Projects 106

Diabetic Neuropathy - Discontinued Products 110

Diabetic Neuropathy - Product Development Milestones 111

Featured News & Press Releases 111

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy 111

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 111

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 112

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 114

Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 114

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 115

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 115

Appendix 116

Methodology 116

Coverage 116

Secondary Research 116

Primary Research 116

Expert Panel Validation 116

Contact Us 116

Disclaimer 117

List of Tables

List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2016 10

Number of Products under Development for Diabetic Neuropathy – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2016 20

Diabetic Neuropathy – Pipeline by Achelios Therapeutics, Inc., H2 2016 21

Diabetic Neuropathy – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 22

Diabetic Neuropathy – Pipeline by Celgene Corporation, H2 2016 23

Diabetic Neuropathy – Pipeline by Commence Bio, Inc., H2 2016 24

Diabetic Neuropathy – Pipeline by Glucox Biotech AB, H2 2016 25

Diabetic Neuropathy – Pipeline by KPI Therapeutics, Inc., H2 2016 26

Diabetic Neuropathy – Pipeline by Lpath, Inc., H2 2016 27

Diabetic Neuropathy – Pipeline by Medifron DBT Co., Ltd., H2 2016 28

Diabetic Neuropathy – Pipeline by Neuralstem, Inc., H2 2016 29

Diabetic Neuropathy – Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016 30

Diabetic Neuropathy – Pipeline by Novartis AG, H2 2016 31

Diabetic Neuropathy – Pipeline by Omeros Corporation, H2 2016 32

Diabetic Neuropathy – Pipeline by PhiloGene, Inc., H2 2016 33

Diabetic Neuropathy – Pipeline by Reata Pharmaceuticals, Inc., H2 2016 34

Diabetic Neuropathy – Pipeline by Relief Therapeutics S.A., H2 2016 35

Diabetic Neuropathy – Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 36

Diabetic Neuropathy – Pipeline by ViroMed Co Ltd, H2 2016 37

Assessment by Monotherapy Products, H2 2016 38

Number of Products by Stage and Target, H2 2016 40

Number of Products by Stage and Mechanism of Action, H2 2016 43

Number of Products by Stage and Route of Administration, H2 2016 46

Number of Products by Stage and Molecule Type, H2 2016 48

Diabetic Neuropathy – Dormant Projects, H2 2016 106

Diabetic Neuropathy – Dormant Projects (Contd..1), H2 2016 107

Diabetic Neuropathy – Dormant Projects (Contd..2), H2 2016 108

Diabetic Neuropathy – Dormant Projects (Contd..3), H2 2016 109

Diabetic Neuropathy – Discontinued Products, H2 2016 110

List of Figures

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2016 10

Number of Products under Development for Diabetic Neuropathy – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 38

Number of Products by Top 10 Targets, H2 2016 39

Number of Products by Stage and Top 10 Targets, H2 2016 39

Number of Products by Top 10 Mechanism of Actions, H2 2016 42

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 42

Number of Products by Routes of Administration, H2 2016 45

Number of Products by Stage and Routes of Administration, H2 2016 45

Number of Products by Molecule Types, H2 2016 47

Number of Products by Stage and Molecule Types, H2 2016 47

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports